These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34785582)

  • 1. Agrin Loss in Barrett's Esophagus-Related Neoplasia and Its Utility as a Diagnostic and Predictive Biomarker.
    Rickelt S; Neyaz A; Condon C; Whittaker CA; Zaidi AH; Taylor MS; Abbruzzese G; Mattia AR; Zukerberg L; Shroff SG; Yilmaz OH; Yilmaz O; Wu EY; Choi WT; Jobe BA; Odze RD; Patil DT; Deshpande V; Hynes RO
    Clin Cancer Res; 2022 Mar; 28(6):1167-1179. PubMed ID: 34785582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
    Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
    Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus.
    Hennig EE; Mikula M; Orlowska J; Jarosz D; Bielasik A; Regula J; Ostrowski J
    J Mol Med (Berl); 2008 Feb; 86(2):233-42. PubMed ID: 17952395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a robust and compact deep learning system for primary detection of early Barrett's neoplasia: Initial image-based results of training on a multi-center retrospectively collected data set.
    Fockens KN; Jukema JB; Boers T; Jong MR; van der Putten JA; Pouw RE; Weusten BLAM; Alvarez Herrero L; Houben MHMG; Nagengast WB; Westerhof J; Alkhalaf A; Mallant R; Ragunath K; Seewald S; Elbe P; Barret M; Ortiz Fernández-Sordo J; Pech O; Beyna T; van der Sommen F; de With PH; de Groof AJ; Bergman JJ
    United European Gastroenterol J; 2023 May; 11(4):324-336. PubMed ID: 37095718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett's Esophagus.
    Waterhouse DJ; Januszewicz W; Ali S; Fitzgerald RC; di Pietro M; Bohndiek SE
    Cancer Res; 2021 Jun; 81(12):3415-3425. PubMed ID: 34039635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
    Ahmad J; Arthur K; Maxwell P; Kennedy A; Johnston BT; Murray L; McManus DT
    Dis Esophagus; 2015 Apr; 28(3):276-82. PubMed ID: 24612412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential application of p53 as an intermediate biomarker in Barrett's esophagus.
    Jones DR; Davidson AG; Summers CL; Murray GF; Quinlan DC
    Ann Thorac Surg; 1994 Mar; 57(3):598-603. PubMed ID: 8147627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance in Barrett's esophagus: an audit of practice.
    Ajumobi A; Bahjri K; Jackson C; Griffin R
    Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical use of p53 in Barrett's esophagus.
    Keswani RN; Noffsinger A; Waxman I; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus.
    Alvi MA; Liu X; O'Donovan M; Newton R; Wernisch L; Shannon NB; Shariff K; di Pietro M; Bergman JJ; Ragunath K; Fitzgerald RC
    Clin Cancer Res; 2013 Feb; 19(4):878-88. PubMed ID: 23243219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining an abnormal p53 immunohistochemical stain in Barrett's oesophagus-related dysplasia: a single-positive crypt is a sensitive and specific marker of dysplasia.
    Tomaszewski KJ; Neyaz A; Sauder K; Rickelt S; Zhang ML; Yilmaz O; Crotty R; Shroff S; Odze R; Mattia A; Patil DT; Deshpande V
    Histopathology; 2023 Mar; 82(4):555-566. PubMed ID: 36458877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genomic biomarker-based model for cancer risk stratification of non-dysplastic Barrett's esophagus patients after extended follow up; results from Dutch surveillance cohorts.
    Hoefnagel SJM; Mostafavi N; Timmer MR; Lau CT; Meijer SL; Wang KK; Krishnadath KK
    PLoS One; 2020; 15(4):e0231419. PubMed ID: 32282835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study.
    Hadjinicolaou AV; van Munster SN; Achilleos A; Santiago Garcia J; Killcoyne S; Ragunath K; Bergman JJGHM; Fitzgerald RC; di Pietro M
    EBioMedicine; 2020 Jun; 56():102765. PubMed ID: 32460165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.
    Hardwick RH; Shepherd NA; Moorghen M; Newcomb PV; Alderson D
    Gut; 1994 Jun; 35(6):764-8. PubMed ID: 8020801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers of Barrett's Esophagus: From the Laboratory to Clinical Practice.
    Konda VJA; Souza RF
    Dig Dis Sci; 2018 Aug; 63(8):2070-2080. PubMed ID: 29713984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Nondysplastic Barrett's Esophagus: A Spatial-Temporal Analysis.
    Frei NF; Konte K; Bossart EA; Stebbins K; Zhang Y; Pouw RE; Critchley-Thorne RJ; Bergman JJGHM
    Clin Transl Gastroenterol; 2020 Oct; 11(10):e00244. PubMed ID: 33108124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SpaTemp cohort: 168 nondysplastic Barrett's esophagus surveillance patients with and without progression to early neoplasia to evaluate the distribution of biomarkers over space and time.
    Frei NF; Konté K; Duits LC; Klaver E; Ten Kate FJ; Offerhaus GJ; Meijer SL; Visser M; Seldenrijk CA; Schoon EJ; Weusten BLAM; Schenk BE; Mallant-Hent RC; Bergman JJ; Pouw RE
    Dis Esophagus; 2021 Mar; 34(3):. PubMed ID: 32944737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.
    Critchley-Thorne RJ; Duits LC; Prichard JW; Davison JM; Jobe BA; Campbell BB; Zhang Y; Repa KA; Reese LM; Li J; Diehl DL; Jhala NC; Ginsberg G; DeMarshall M; Foxwell T; Zaidi AH; Lansing Taylor D; Rustgi AK; Bergman JJ; Falk GW
    Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):958-68. PubMed ID: 27197290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.